Driving Scripts and Improving AQ: How DeepIntent Outcomes Delivers for Pharma Advertisers

There are more than 20,000 prescription drugs approved for marketing by the Food and Drug Administration (FDA). And yet, they all have one big thing in common: Driving script performance is a goal of theirs.

Pharma advertisers need fast, transparent, actionable measurement. This provides timely insights and powers the automatic, real-time optimizations that enable them to influence and optimize their healthcare provider (HCP) and patient campaigns through the funnel. Ultimately, they must answer these questions: Are they reaching the right verified patients and HCPs? Are they meeting in a clinical setting? Are they writing and filling scripts?

Only DeepIntent Outcomes™—the industry’s fastest measurement solution based on clinical data—offers daily audience quality (AQ) and script lift metrics. These help pharma brands answer those questions and achieve their goals: driving script performance metrics such as total prescriptions (TRx) and new prescription starts (NPS); improving audience quality (AQ); and reaching the right verified patients and healthcare providers (HCPs), all while decreasing their cost-pers.

Driving Scripts and Improving AQ

With patented technology that links real-world clinical data with impression data, Outcomes’ machine learning algorithms automatically optimize campaigns toward AQ and script performance. The algorithms spend three or four weeks “learning” how to best reach the highest-value patients and HCPs, or those most likely to prescribe your brand, ultimately driving scripts. From there, ongoing machine learning and bid optimization maximize script volume at the lowest possible cost.

Outcomes is currently used across more than 1,200 campaigns by more than 115 brands. One of those brands is an antiviral medication used to treat symptoms of an infectious disease. Outcomes optimizations improved AQ for all audiences, including third-party segments onboarded from industry-leading data providers. That delivered 865% greater AQ vs. the disease prevalence in the U.S. population. Ads reached patients who were more likely to be condition sufferers, ultimately driving scripts. The campaign contributed to more than 2,400 incremental scripts.

To learn more, download Revolutionizing Healthcare Advertising: How DeepIntent Outcomes™ Delivers Exceptional Performance for Leading Pharma Brands, which also includes pharma brands’ success stories such as:

  • Increasing AQ by up to 164% throughout a campaign
  • Driving scripts by 154% with a combination of connected TV, online video, and display
  • Influencing 27% script lift within a campaign’s first 120 days
  • Growing verified patient reach while reducing cost-per-verified patient (CPVP) by 37%
  • And more!

Share this Post

Related Articles

Precision is currency in the rapidly changing world of health advertising, especially for pharma brands seeking to drive vaccine awareness. Vaccine campaigns—for both communicable and non-communicable diseases—are most effective when they reach the right audience at the right time. The Unique Challenges of Vaccine Advertising Vaccine advertising is different from a typical pharmaceutical campaign in […]

Last week marked the official launch of The DeepDive, a brand-new destination for health advertising insights, education, and community. The DeepDive shares actionable health intelligence while exploring the topics and trends that matter most to our industry, including technology, privacy, identity, and more. Maybe you’re already familiar with our mission: to improve patient outcomes through […]

As health marketing undergoes rapid disruption around privacy and identity, delivering personalized messaging at scale becomes a steeper challenge—and an even more important goal. It isn’t just about “selling” more products. It’s about finding new ways to reach people and improve health outcomes. At AdLab Health Marketing Summit, DeepIntent Founder and CEO Chris Paquette urged […]

Never Miss New Insights

Sign up for the newsletter to ensure our latest whitepapers, research reports, and more are delivered to your inbox.